Synergy and competition between cancer genome sequencing and epigenome mapping projects by Christoph Bock
Bock Genome Medicine 2014, 6:41
http://genomemedicine.com/content/6/5/41COMMENTSynergy and competition between cancer genome
sequencing and epigenome mapping projects
Christoph Bock1,2,3Editorial summary
Large-scale projects in the fields of cancer genomics
and epigenomics have different aims, cultures and
outcomes. The author argues that by working together
a complete picture of cancer biology could be painted,
and he advocates the creation of an International
Cancer Epigenome Consortium.cancer genes [1], in much the same way as the field of
genetic epidemiology is working on a comprehensiveLarge international consortia are currently pursuing
massive sequencing of cancer genomes and comprehen-
sive characterization of the human epigenome. Both
research directions have already proven their value, un-
covering exciting biology and creating promising direc-
tions for novel therapies. Here, I argue that the two
fields of cancer genomics and epigenomics complement
each other in promoting our understanding of cancer, in
part because they operate under surprisingly different
paradigms. Fostering exchange as well as healthy compe-
tition between research projects following either para-
digm will contribute to a more complete picture of
cancer biology and could provide us with a broader
spectrum of therapeutic opportunities.Cancer genome sequencing: completing the
census of human cancer genes
The concept of cancer as a genetic disease has been well-
established since the 1970s. After the initial sequencing of
the human genome by the Human Genome Project, it was
an obvious next step to explore how cancer genomes are
altered at the DNA sequence level. The Cancer Genome
Atlas (TCGA, http://cancergenome.nih.gov) was launched
in 2005/2006 with a pilot study establishing the feasibility
of large-scale genome characterization in three types ofCorrespondence: cbock@cemm.oeaw.ac.at
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months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/cancer. Building on the success of this pilot, TCGA was
extended to more than 20 different cancers in 2009. Fur-
thermore, the International Cancer Genome Consortium
(ICGC, https://icgc.org/) was founded in 2008 with the
goal of coordinating cancer genome projects worldwide,
comprising 25,000 samples in 50 cancer types.
The defining goal of these large-scale cancer genome
sequencing projects is to establish a complete census of
table of genetic disease risks through massive-scale asso-
ciation studies. The beauty of this approach lies in part
in its clear and measurable goal, but also in the prospect
that very large sample numbers will provide conclusive
statistical evidence for disease relevance even when a
detailed understanding of the biological mechanisms is
lacking. Completing the census of human cancer genes
is expected to contribute not only to improved risk
stratification for cancer patients, but also promises to
systematically identify many new targets for cancer drug
development [2].
However, this reductionist focus on cataloging re-
current genetic alterations is not only a strength but also
a limitation. Because most genetic alterations in cancer
are rare, even an optimistic calculation suggests that it
will take around 100,000 cancer genomes to finalize the
cancer gene census for the most common cancer types
[3], and this number is probably going to increase
because detailed molecular investigations often sub-
divide common cancers into collections of much rarer
diseases. In rare cancers, even a worldwide network for
sample collection would not suffice for building a statis-
tically sound catalog of recurrent genetic alterations.
This problem is further aggravated when combinatorial
effects are taken into account, and for the majority of
patients that present with several rare mutations there
will not be any other patient in the databases with the
exact same combination of mutations.licensee has exclusive rights to distribute this article, in any medium, for 12
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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Whereas cancer genome sequencing assumes that can-
cers are driven by relatively few and well-defined genetic
alterations, epigenetic research has been more inclined
to embrace complexity, stochasticity and interactions
with the environment as key elements of cancer biology
[4]. Epigenetic alterations are as widespread in cancer as
genetic alterations, and they have been observed in every
single tumor sample that has so far been studied using
high-resolution epigenome mapping technology. Fur-
thermore, DNA methylation is mitotically heritable and
strongly associated with gene repression; hence, it is
likely that at least some epigenetic alterations can be
drivers of clonal evolution in much the same way as
genetic alterations. But there is also a global dimension
to epigenetic alterations that distinguishes them from
the localized nature of most genetic alterations. Epigen-
etic profiles are highly cell-type-specific and undergo
reprogramming when cells differentiate, dedifferentiate
or otherwise alter their cell state. Genome-wide alter-
ations of epigenetic marks can also be induced by expo-
sures to environmental influences, and such induced
changes may be maintained across cell divisions even
after the initial stimulus has disappeared.
To create a reference framework for studying epigen-
etics in cancer and other diseases, an international hu-
man epigenome project has been proposed by a working
group of the American Association for Cancer Research
(AACR) in 2005 [5], building upon proof-of-concept
studies in Europe, in the US and elsewhere. This pro-
posal contributed to the establishment of the Roadmap
Epigenomics Project in 2007/2008 (http://www.roadmape-
pigenomics.org) and to the formation of the International
Human Epigenome Consortium (IHEC) in 2010 (http://
ihec-epigenomes.org). Many national and international
initiatives have joined the IHEC in its goal to establish
comprehensive reference epigenomes for a total of 1,000
cell types from healthy and diseased donors. Examples in-
clude the European BLUEPRINT (http://www.blueprint-
epigenome.eu), the German DEEP (http://www.deutsches-
epigenom-programm.de) and the Japanese CREST-IHEC
(http://crest-ihec.jp) projects.
Epigenome projects have been more open-ended than
cancer genome sequencing, pursuing a broader range of
goals and incorporating a larger amount of hypothesis-
driven research. While the study of cancer has always
been central to epigenetic research [6] and continues to
be a major priority, epigenome projects have also con-
tributed substantially to our understanding of pluripo-
tency and cellular differentiation, and the resulting
insights have helped devise improved methods for
cellular reprogramming and in vitro differentiation. The
hematopoietic system has also become a major focus ofongoing epigenome projects, and this relatively ac-
cessible and well-characterized lineage is providing
important insights into the mechanisms of cellular
differentiation in vivo.
Perspectives for an international cancer
epigenome consortium
When the TCGA and ICGC projects were conceived,
epigenome mapping was in its infancy and difficult to
perform on primary tumor samples. Furthermore, there
was substantial skepticism in the cancer genomics com-
munity as to whether epigenetic aberrations were func-
tionally important or maybe just downstream effects of
changes in classical cancer signaling pathways. For these
reasons, epigenome mapping does not play a major role in
ongoing cancer genome projects, where it has largely been
restricted to DNA methylation mapping of preselected
genomic regions using a commercial microarray platform.
However, recent developments have convincingly refuted
both concerns. First, painstaking technology optimization
has made it possible to establish comprehensive epi-
genomes - comprising DNA methylation and its oxidized
variants, multiple histone modifications, chromatin accessi-
bility and the coding and non-coding transcriptome - in
limited amounts of primary patient samples; and ongoing
efforts could even enable genome-wide DNA methylation
analyses in single cells. Second, the important functional
role of epigenetic mechanisms in cancer has been conclu-
sively established by the identification of recurrent genetic
aberrations in several dozen epigenetic regulator genes
across a wide range of cancer types [7].
In light of these recent developments, the AACR working
group that initiated the discussions for the formation of
IHEC has proposed that the time is ripe for establishing an
International Cancer Epigenome Consortium (ICEC),
which could take the concepts of the IHEC forward and
more specifically contribute to the development of new
cancer therapies [8]. The cornerstone of such a project will
be the comprehensive characterization of epigenomes in a
large number of cancer samples. Furthermore, because of
the complexity of cancer epigenomes and the many ways in
which they could contribute to cancer, the mapping com-
ponent should be complemented by: (i) functional studies
dissecting cause and consequence in cancer genomics (for
example, using emerging methods for epigenome editing);
(ii) bioinformatic modeling of the interplay of genetic and
epigenetic changes; (iii) comprehensive characterization of
the mechanisms of action for existing and new epigenetic
drug candidates; and (iv) the development of epigenetic
biomarker candidates into relevant diagnostic assays for
personalized medicine.
A cancer epigenome project designed along these lines
would be highly complementary to existing efforts in
cancer genome sequencing. Its focus on the complexity of
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onment, signaling pathways and cancer drugs would pro-
vide an important counterbalance to the reductionist
approach taken by cancer genome sequencing. Although
there will be some overlap in the experimental assays (for
example, with DNA methylation mapping), the different
analysis paradigms would result in very different conclu-
sions. Rather than cataloging single epigenetic drivers and
their statistical significance, a cancer epigenome project
that is inspired by the success of IHEC could focus on the
concept of epigenetic cell states [9] and cellular re-
programming through individualized combination thera-
pies [10] as novel approaches for interfering with cancer
development, progression and drug resistance. In sum-
mary, the paramount importance of epigenetics in cancer
has been convincingly shown over the course of the past
5 years, and it is unquestionable that an internationally
coordinated and adequately funded initiative in the field
of cancer epigenomics could have major impact.
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